The global defibrillator market, valued at USD 11.29 billion in 2024, is expected to reach USD 16.44 billion by 2030, growing at a CAGR of 6.5%. This steady rise reflects the global commitment to tackling cardiovascular diseases (CVDs)—the leading cause of death worldwide—and improving emergency cardiac care accessibility.
Driving Forces Behind the Market Growth
The surge in defibrillator adoption is largely attributed to several key factors:
- Rising prevalence of cardiovascular diseases: The increasing incidence of cardiac arrest and related conditions, particularly among aging populations, has created a significant need for defibrillator deployment.
- Government-led initiatives: Governments across major economies are promoting public access defibrillator (PAD) installations and training programs to strengthen emergency response systems.
- Technological innovation: Manufacturers are advancing product designs with AI-enabled monitoring, wireless connectivity, and remote diagnostics, making defibrillators more efficient and user-friendly.
- Expanding healthcare infrastructure in emerging economies: Investments in healthcare modernization, particularly across Asia-Pacific, are opening new avenues for defibrillator adoption.
By product, the defibrillators market is broadly segmented into implantable cardioverter defibrillators (ICDs) and external defibrillators. The implantable cardioverter defibrillators (ICDs) segment is anticipated to capture the largest global defibrillator market share by product in 2024. Timely intervention using implantable defibrillators during cardiac emergencies is a key advantage offered by this programmed device. Moreover, growing approvals of technologically advanced implantable defibrillators and rising preference for subcutaneous ICDs are likely to support the growth of this segment during the forecast period.
By end users, the defibrillators market is segmented into Hospitals & Clinics, Cardiac Centers, Pre-hospital Settings, Public-Access Markets, Home Care Settings, and Other End Users. The hospitals & clinics segment dominated the global defibrillators market in 2024. The significant rise in hospitalization for critical cardiac conditions, the growing number of ICD and CRT-D implant procedures performed in hospitals, and the rising prevalence of cardiac diseases among geriatric patients are the major factors boosting the demand for defibrillators among target end-user segments during the study period.
By geography, the defibrillator market is segmented based on the region into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the largest share of the defibrillator market. This can be attributed to the rapid adoption of technologically advanced defibrillators, favorable reimbursement policy, and the strong presence of manufacturers with a strong focus on strengthening R&D through investments in new product development. Asia Pacific is expected to grow at the highest CAGR during the forecast period owing to the presence of a large target patient pool, government initiatives to modernize & expand healthcare infrastructure, and expansion of market players in the region.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=549
Major players in the defibrillator market include Medtronic (Ireland), Stryker (US), Koninklijke Philips N.V. (Netherlands), Asahi Kasei Corporation (Japan), Boston Scientific Corporation (US), Abbott (US), MicroPort Scientific Corporation (China), Nihon Kohden Corporation (Japan), Biotronik (Germany), and CU Medical Systems, Inc. (South Korea).
MEDTRONIC:
MEDTRONIC Due to its extensive product portfolio, Medtronic is the leading player in the global implantable defibrillator market. The company primarily focuses on developing innovative products to treat and manage heart failure and heart rhythm disorders. The company focuses on inorganic business growth strategies such as product development & commercialization, acquisitions, and market expansions to strengthen its current position and gain a larger share of the neurovascular devices market. The company received the CE Mark for its implantable defibrillator systems, Aurora EV-ICD MRI SureScan and Epsila EV MRI SureScan for managing irregular heart rhythms. Moreover, the company is also focusing on expanding its R&D capabilities to fuel product development and commercialization across mature and emerging markets.
Koninklijke Philips N.V.
Koninklijke Philips N.V. is a key player in the global defibrillator market, driven by its widely adopted HeartStart AED series. The company has established a strong presence through user-friendly, reliable devices designed for both public and professional use. Philips continues to lead with innovations such as real-time guidance, fast shock delivery, and connected care capabilities. Its strategic focus on accessibility, digital integration, and global deployment has reinforced its role in advancing out-of-hospital cardiac care.
Boston Scientific Corporation
Boston Scientific Corporation focuses on innovation and product launches in cardiac rhythm management to provide advanced solutions to healthcare professionals to improve the quality of life. The company continuously invests in R&D to launch new & innovative products. Boston Scientific primarily pursues the strategy of new product launches to sustain its position in the global defibrillators market. Regulatory approvals for its MRI-compatible defibrillators and technological advancements are expected to help the company maintain its position in the market.
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email:Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/automated-external-defibrillator-market-549.html
